Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency

NCT02408484 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02408484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02408484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
June 11, 2019
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

congenital fibrinogen deficiency